What they found
Developed a multicolor mechanoluminescence platform that converts focused ultrasound into tunable light emission (461-592 nm) using ROS-responsive chemiluminescent donors coupled to fluorescent acceptors via FRET. Established a design principle: electronic energy gap-dependent ROS generation predicts material performance. Successfully activated three different optogenetic actuators (ChR2, eOPN3, ChRmine) under focused ultrasound for noninvasive deep-tissue neuromodulation.
Lateral connection
This directly bridges ultrasound energy to optogenetic control in deep tissue — the exact capability needed for our sonogenetics hypothesis applied to inner ear hair cells. The cochlea is acoustically accessible by definition. If mechanoluminescent nanoparticles could be delivered to the organ of Corti, focused ultrasound could activate light-sensitive ion channels in hair cells, providing a non-genetic alternative or complement to gene therapy. The tunable emission wavelength (blue to red) means compatibility with multiple channelrhodopsin variants, and red-shifted emission would minimize phototoxicity in the sensitive cochlear environment.
Hypothesis suggested
Mechanoluminescent nanoparticles delivered to the perilymph could convert cochlear sound-frequency vibrations or externally applied FUS into local light emission, activating optogenetic channels in transduced hair cells. This creates a hybrid sono-optogenetic cochlear prosthesis: AAV delivers the channelrhodopsin, nanoparticles provide the light source triggered by sound itself.
What could be computed
Acoustic field modeling of the cochlea to determine: (1) whether cochlear mechanics generate sufficient local pressure to trigger mechanoluminescence, (2) optimal nanoparticle positioning relative to outer hair cells, (3) required nanoparticle concentration to achieve threshold photon flux for channelrhodopsin activation at relevant frequencies.
Links
Connections
[source]auto-indexed 2026-04-20 by strc-lit-watch